Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 6, 2009, Pages 553-557

  Ibrahim, Murad ^a,b,c,d   Truffot Pernot, Chantal ^a,b,c   Andries, Koen ^e   Jarlier, Vincent ^a,b,c   Veziris, Nicolas ^a,b,c,f  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔpital Robert Debré   (France)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e TIBOTEC BVBA   (Belgium)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Diarylquinoline; Experimental chemotherapy; Mycobacterium tuberculosis; R207910; Sterilizing activity; TMC207

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT S; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; SWISS WEBSTER MOUSE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HYDROLASES; ISONIAZID; MICE; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; QUINOLINES; RIFAMPIN; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; TUBERCULOSIS, SPLENIC;

EID: 69949107758     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200807-1152OC     Document Type: Article

References (26)

1. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227. (Pubitemid 40116230)
2. Ballell L, Field RA, Duncan K, Young RJ. New small-molecule synthetic antimycobacterials. Antimicrob Agents Chemother 2005;49:2153-2163.
3. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-966. (Pubitemid 30435054)
4. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. Opc-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466. (Pubitemid 44875946)
5. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426. (Pubitemid 38134824)
6. Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N. Synergistic activity of r207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51:1011-1015. (Pubitemid 46355288)
7. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006;50:3543-3547. (Pubitemid 44684863)
8. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, et al. The diarylquinoline tmc207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360:2397-2405.
9. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Gohlmann HW, Willebrords R, Poncelet A, Guillemont J, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed atp homeostasis. J Biol Chem 2008;283:25273-25280.
10. McCune RM Jr, McDermott W, Tompsett R. The fate of mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique: II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956;104:763-802.
11. McCune RM Jr, Tompsett R. Fate of mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique: I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956;104:737-762.
12. Grosset J, Truffot C, Fermanian J, Lecoeur H. Activité stérilisante des différents antibiotiques dans la tuberculose expérimentale de la souris. Pathol Biol (Paris) 1982;30:444-448. (Pubitemid 12081204)
13. Veziris N, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob Agents Chemother 2005;49:4015-4019. (Pubitemid 41400940)
14. Veziris N, Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V. R207910 containing regimens display high sterilizing activity in the murine model of tuberculosis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2007.
15. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992;36:548-551.
16. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-1134. (Pubitemid 39488628)
17. Truffot-Pernot C, Ji B, Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle 1991;72:57-64.
18. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978;53:5-12. (Pubitemid 9243249)
19. Dickinson JM, Mitchison DA. Efficacy of intermittent pyrazinamide in experimental murine tuberculosis. Tubercle 1991;72:110-114.
20. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 1989;140:1189-1193. (Pubitemid 19276194)
21. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (at-4140) against mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413. (Pubitemid 23072581)
22. Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. A once-weekly r207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med 2009;179:75-79.
23. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007;4:e344.
24. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline tmc207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-2835.
25. Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH. Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agents Chemother 2007;51:403 (author reply 403-404).
26. Lenaerts AJ, Chapman PL, Orme IM. Statistical limitations to the cornell model of latent tuberculosis infection for the study of relapse rates. Tuberculosis (Edinb) 2004;84:361-364.